Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New brain test aims to unravel language confusion in dementia

NCT ID NCT07573046

Diagnosis Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new cognitive assessment called the ExéSem battery, designed to help doctors tell the difference between language problems caused by memory loss versus those caused by thinking difficulties. Researchers will enroll 140 people, including those with Alzheimer's disease, vascular cognitive impairment, a specific language disorder, and healthy volunteers. Participants will complete tasks like matching words to pictures and naming objects quickly, with results used to see if the battery can accurately identify the root cause of language issues.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ExéSem cognitive battery (a neuropsychological assessment tool)
What this could lead to
If successful, this battery could help doctors more accurately diagnose whether language problems are due to memory loss or thinking difficulties.
What could go wrong
This is an early validation study, not a treatment trial. The battery may not prove reliable enough for widespread use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes two groups aged 50 to 90 years: cognitively healthy participants and patients with mild to moderate neurocognitive disorders (MMSE ≥20/30), including Alzheimer's disease, vascular neurocognitive disorder, or semantic variant primary progressive aphasia. Healthy participants are recruited on a voluntary basis through flyers displayed in the Charpennes Hospital and distributed by speech therapy and neuropsychology students. Interested individuals contact the Clinical Research Center (CRC), where they receive initial information during a phone call and are provided with the study information sheet before scheduling an inclusion visit. Patients with neurocognitive disorders are recruited during routine clinical care (consultation or day hospital assessment).

Ages

50 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Participants without cognitive impairment * Participant aged 50 to 90 years (inclusive); * Participant whose native language is French * Participant affiliated with or entitled to a social security scheme; * Participants who have been informed and have not objected. * Participants with cognitive impairment * Participant aged 50 to 90 years (inclusive); * Participant whose native language is French * Participant receiving memory care with a diagnosis of Alzheimer's disease, at the stage of minor or major neurocognitive impairment, according to the 2011 NIA-AA criteria (McKahn et al., 2011), or with a diagnosis of vascular neurocognitive impairment according to the VasCog-2-WSO diagnostic criteria (Sachdev et al., 2025), or with a diagnosis of primary progressive aphasia with semantic variant (Gorno-Tempini et al., 2011). * Mini-Mental State Examination (MMSE) score ≥ 20/30, within the 6 months preceding enrollment; * Participants affiliated with or entitled to a social security scheme; * Participants who have been informed and have not objected. Exclusion Criteria: * \- For all participants: * Severe, progressive, or unstable medical conditions that may interfere with assessment variables (epilepsy, acute psychiatric or psychotic disorders, visual hallucinations, acute infection); * Substance use that may affect cognitive performance; * Deafness or blindness that may compromise the participant's assessment or participation in tasks and scales; * Participants under guardianship, curatorship, or legal protection; * Pregnant, postpartum, or breastfeeding women. * Specifically for participants without cognitive impairment: * Participants previously diagnosed with cognitive impairment. * Specifically for participants with cognitive impairment: * Severe behavioral and psychological symptoms that prevent task completion, as determined by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease cognitive disorder nominal aphasia semantic dementia vascular dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer's disease People without neurocognitive disorder Progressive primary aphasia semantic variant Vascular neurocognitive disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hopital des CHARPENNES ( Hospices Civils de Lyon)

    Lyon, 69100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.